Sanofi US News

Dupixent significantly improved skin clearance and reduced overall disease severity and itch in a Pivotal trial that met all primary and secondary endpoints

Sarclisa combination therapy is first to demonstrate superiority to standard of care lenalidomide, bortezomib and dexamethasone (RVd) in a Phase 3 trial

Dupixent significantly reduced severe asthma attacks and improved lung function and asthma control in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma

* Regardless of gender or sexual orientation, employees welcoming a child into their family receive equal amount of paid time off

Andrew Drechsler to Retire as Chief Financial Officer in December

PRV-101 was well tolerated and elicited high titers of virus-neutralizing antibodies in a dose-dependent fashion in healthy volunteers

Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial

Pivotal trial met primary and all key secondary endpoints

Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option

First study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older

Presentations focused on respiratory syncytial virus, meningococcal disease, and influenza

*Phase 3 trial met its primary and key secondary endpoints

Data collection completed for PROTECT Pharmacokinetic/Pharmacodynamic (PK/PD) substudy